Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-166089)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-05737)
Article History
Received: 12 January 2023
Accepted: 29 March 2023
First Online: 25 April 2023
Competing interests
: SV has 60% ownership of Regulatory Cell Therapy Consultants Inc., which does not conflict with this paper in any way. KR and GC declare no conflicts of interest.